Incyte Says FDA Grants Priority Review For Eczema Cream

Incyte announced that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of its ruxolitinib cream. Shares of the biopharmaceutical company declined around 1.2% to close at $80.54 on Feb. 19.